Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor M Rivera

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Rana Anjum, Rachel Squillace, et al.
Cancer Discovery|February 26, 2021
Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung CancerFrancois Gonzalvez, Sylvie Vincent, Theresa E Baker, et al.
The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Cancer Research|August 12, 2021
Targeting <i>HER2</i> Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor MobocertinibHan Han, Shuai Li, Ting Chen, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.
Journal of Medicinal Chemistry|May 5, 2016
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma KinaseWei-Sheng Huang, Shuangying Liu, Dong Zou, et al.
Multiple Sclerosis and Related Disorders|February 15, 2025
Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGADDeyanira A Ramirez, Fernando Gracia, Alejandro J Diaz Jimenez, et al.
Journal of Medicinal Chemistry|June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Rana Anjum, Rachel Squillace, et al.
Cancer Discovery|February 26, 2021
Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung CancerFrancois Gonzalvez, Sylvie Vincent, Theresa E Baker, et al.
The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Cancer Research|August 12, 2021
Targeting <i>HER2</i> Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor MobocertinibHan Han, Shuai Li, Ting Chen, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.
Journal of Medicinal Chemistry|May 5, 2016
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma KinaseWei-Sheng Huang, Shuangying Liu, Dong Zou, et al.
Multiple Sclerosis and Related Disorders|February 15, 2025
Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGADDeyanira A Ramirez, Fernando Gracia, Alejandro J Diaz Jimenez, et al.
Journal of Medicinal Chemistry|June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.
Pageof 10